This product review focusses on the use of Apixaban for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment and prevention of venous thromboembolism.
This review discusses pharmacological properties, mechanism of action and major studies featuring Apixaban. It also provides commentary and recommendations from Professor Miles Prince and Dr Anna Parakh.
Please login below to download this issue (PDF)